Britain could give regulatory approval to Pfizer-BioNTech’s COVID-19 vaccine this week, even before the United States authorises it, the Telegraph news site reported on Sunday.
Citing government sources, it said British regulators were about to start a formal appraisal of the vaccine, made by Pfizer Inc and BioNTech SE, and that the National Health Service had been told to be ready to administer it by Dec. 1.
The U.S. Food and Drug Administration said on Friday that it would meet on Dec. 10 to discuss whether to authorise the vaccine.
The UK Department of Health had no comment on Sunday on when the first vaccinations would be administered.
A spokesman said the authorisation process by the medical regulator Medicines and Healthcare Products Regulatory Agency (MHRA) is independent of the government and will take as long as they need to review the final data from Pfizer.
“An enormous amount of planning has taken place to ensure our health service stands ready to roll out a COVID-19 vaccine,” the spokesman added.
Britain formally asked its medical regulator, the MHRA, last week to assess the suitability of the Pfizer-BioNTech vaccine.
Britain has ordered 40 million doses and expects to have 10 million doses, enough to protect 5 million people, available by the end of the year if regulators approve it.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.